Abstracts Archive - Page 68 of 2607 - ACR Meeting Abstracts

Abstract Number: 0931 • ACR Convergence 2025
Reduced mitophagy in salivary glands of Sjögren’s disease patients is associated with mitochondrial structural damage
Salvador Campos¹, Sergio Aguilera², Juan Gutiérrez¹, Isabel Castro³, Patricia Carvajal³, Lorena Carvajal¹, Sergio González⁴, Claudio Molina⁵, María-Julieta González⁶ and María-José Barrera⁵, ¹Universidad San Sebastián, Santiago, Region Metropolitana, Chile, ²Clinica Indisa, Santiago, Region Metropolitana, Chile, ³Departamento de Tecnología Médica, Facultad de Medicina, Universidad de Chile, Santiago, Region Metropolitana, Chile, ⁴Escuela de Odontología, Universidad Mayor, Santiago, Region Metropolitana, Chile, ⁵Facultad de Odontología, Universidad San Sebastián, Santiago, Region Metropolitana, Chile, ⁶ICBM, Facultad de Medicina, Universidad de Chile, Santiago, Region Metropolitana, Chile
Background/Purpose: Primary Sjögren's disease (pSjD) is a systemic autoimmune disease characterized mainly by immune-mediated damage to exocrine glands. Previously, we found decreased expression of ATG5…
Abstract Number: 0603 • ACR Convergence 2025
Transverse Myelitis in Systemic Lupus Erythematosus: Disease Manifestations and Clinical Outcomes from Multi-Center Data
Amir Daneshvar¹, Areeb Tiwana², Dana Nachawati¹, Keri Ann Pfeil¹, Elleson Harper¹, Lindsay Frumker³, Meghan Gump¹ and Omer Pamuk⁴, ¹University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, ²Canton Medical Education Foundation, Canton, OH, ³University hospitals Cleveland medical center, Highland Heights, OH, ⁴University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease with widespread clinical manifestations. Neuropsychiatric SLE (NPSLE), a complex and poorly understood subset of SLE,…
Abstract Number: 2284 • ACR Convergence 2025
Cardiovascular Outcomes in Diabetic Rheumatoid Arthritis Patients: TNF-α Inhibitors versus IL-6 Inhibitors
Sila Mateo Faxas¹, Godbless Ajenaghughrure¹, Gurjot Singh², Kim Nguyen², Nirys Mateo Faxas³, Nicole Tejeda⁴, Kimberly Ramirez Bonetti⁵ and Erick Perez Mejias⁴, ¹Trihealth Good Samaritan Hospital, Cincinnati, OH, ²Trihealth Good Samaritan Hospital, Cincinnati, ³Independent Author, Santo Domingo, Dominican Republic, ⁴Independent Author, Cincinnati, ⁵Independent Author, cincinnati, OH
Background/Purpose: Patients with rheumatoid arthritis (RA) and type 2 diabetes mellitus (T2DM) face increased cardiovascular risk. Different biologic disease-modifying antirheumatic drugs (bDMARDs) may have varying…
Abstract Number: 0925 • ACR Convergence 2025
Pathogenic role of SPP1+ macrophages in Rheumatoid Arthritis
Megan M. Hanlon¹, Catherine Manning¹, Kevin Wei¹, Ursula Fearon² and Ellen M. Gravallese³, ¹Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ²Trinity College Dublin, Dublin, Dublin, Ireland, ³Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA
Background/Purpose: Synovial tissue macrophages (STMs) represent a mixed population of cells contributing to the pathogenesis of rheumatoid arthritis (RA). We identified an enrichment of Secreted…
Abstract Number: 0932 • ACR Convergence 2025
Compartment-specific NK-cell phenotypes reveal distinct maturation and activation states in inflammatory arthritis
Franca Sophie Deicher¹, Tarik Exner², Maren Claus³, Schayan Yousefian⁴, Lea Rodon⁵, sophie leonhardt⁶, Jörg Distler⁷, Carsten Watzl³, Hanns-Martin Lorenz⁸, Simon Haas⁴, Daniel Hübschmann⁹ and Wolfgang Merkt¹⁰, ¹Uniklinik Düsseldorf, Düsseldorf, Germany, ²University Hospital Heidelberg, Heidelberg, Germany, ³IfADo, Leibniz Institute Dortmund, Dortmund, Germany, ⁴Charite, Berlin, Berlin, Germany, ⁵University Hospital Heidelberg, Heidelberg, Hungary, ⁶Heidelberg University, Heidelberg, Germany, ⁷University Hospital Duesseldorf and HHU, Duesseldorf, Germany, ⁸Universitétsklinikum Heidelberg, Heidelberg, Germany, ⁹Heidelberg University, Berlin, Germany, ¹⁰University Hospital Düsseldorf, Düsseldorf, Germany
Background/Purpose: Synovial natural killer (NK) cells contribute to inflammation in arthritis by secreting cytokines and modulating synovial fibroblast activation. The aim of this study is…
Abstract Number: 0612 • ACR Convergence 2025
Is Antimalarial Use Associated with a Reduced Risk of Lupus Nephritis in Patients with SLE? Results from an Inception Cohort-Based Study
Fadi Kharouf¹, JuanPablo Diaz Martinez², Pankti Mehta³, Dafna D. Gladman⁴, Laura Whitall Garcia⁵ and Zahi Touma⁶, ¹University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ²Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³University of Toronto, Gladman Krembil Psoriatic Arthritis Research Program, Toronto, ON, Canada, ⁴Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁵University Health Network, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada
Background/Purpose: Antimalarials, particularly hydroxychloroquine, are a cornerstone of systemic lupus erythematosus (SLE) management, with well-established benefits including reduced disease activity, prevention of flares, and mitigation…
Abstract Number: 0508 • ACR Convergence 2025
Serum immune complexes assessed using a cell-reporter assay are associated with serum IFN-alpha levels, disease activity and the risk of incident lymphoma in the ASSESS prospective cohort
Clementine Pouenat¹, Marine Vierling², Chiara Meier³, Ludivine Robin⁴, Philippe Kolb⁵, Hartmut Hengel⁶, Gaetane Nocturne⁷, Divi Cornec⁸, Valerie Devauchelle⁹, Véronique Le Guern¹⁰, Claire larroche¹¹, Damien Sène¹², Marion Couderc¹³, Eric HACHULLA¹⁴, Philippe Dieude¹⁵, Olivier Vittecoq¹⁶, Jacques Morel¹⁷, Nicolas Meyer¹⁸, Raphaele Seror¹⁹, Reinhard Voll²⁰, Pierre-Marie Duret²¹, Laurent Miguet²², Xavier Mariette²³ and Jacques-eric GOTTENBERG²⁴, ¹IBMC, UPR ³⁵⁷², STRASBOURG, France, ²Strasbourg University Hospital, Department of Public Health, GMRC, Strasbourg, France,, Strasbourg, Alsace, France, ³Strasbourg University Hospital, Department ofRheumatology, STRASBOURG, France, ⁴Strasbourg University Hospital, Department of pathology, ⁴CNRS, Immunopathologie et Chimie Thérapeutique/Laboratory of Excellence Medalis, Institut de Biologie Moléculaire et Cellulaire (IBMC), Strasbourg, France Strasbourg, France;, Strasbourg, Alsace, France, ⁵INSTITUTE OF VIROLOGY Medical Center, Freiburg, Freiburg, Germany, ⁶INSTITUTE OF VIROLOGY University Hospital Freiburg, FREIBURG, Germany, ⁷University Paris Saclay, Le Kremlin Bicetre, Ile-de-France, France, ⁸LBAI, UMR¹²²⁷, University of Brest, CHU Brest, Brest, France, Brest, Bretagne, France, ⁹UBO, Brest, France, ¹⁰Cochin hospital, Paris, France, ¹¹Service de Médecine Interne, Hôpital Avicenne APHP, Bobigny, Paris, Ile-de-France, France, ¹²Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, Paris, Ile-de-France, France, ¹³Service de Rhumatologie CHU Clermont-Ferrand, Clermont-Ferrand, ¹⁴CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-Immunes et Auto-Inflammatoires Rares du Nord, Nord-Ouest, Méditerranée et Guadeloupe (CeRAINOM), Lille, France, Lille, France, ¹⁵Service de Rhumatologie, Hôpital Bichat APHP, Paris, Paris, Ile-de-France, France, ¹⁶Service de Rhumatologie & CIC-CRB ¹⁴⁰⁴, CHU de Rouen, Université de Rouen, Rouen, Rouen, France, ¹⁷CHU and University of Montpellier, Montpellier, France, ¹⁸Strasbourg University Hospital, Department of Public Health, GMRC, Strasbourg, France, Strasbourg, Alsace, France, ¹⁹Department of Rheumatology, National referral center for auto immune disease and Sjogren disease, Université Paris-Saclay, INSERM UMR¹¹⁸⁴: Centre for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, Paris, France., le kremlin bicetre, France, ²⁰University Medical Center Freiburg, Freiburg, Germany, ²¹Colmar General Hospital; Strasbourg University Hospital, Strasbourg, France, ²²Haemtology, Strasbourg University Hospital, IBMC UPR ³⁵⁷², Strasbourg, France, ²³Université Paris-Saclay, Le Kremlin Bicetre, France, ²⁴Hautepierre Hospital, STRASBOURG, Alsace, France
Background/Purpose: Fc‐gamma receptor (FcγR) activation by soluble IgG immune complexes (sICs) is considered to play a pivotal pathogenic role in B-cell-mediated autoimmune diseases, such as…
Abstract Number: 0941 • ACR Convergence 2025
In Vivo PanCAR Therapy Utilizing Circular RNA for Treatment of Autoimmune Diseases
Juliet Crabtree, Thomas Lee, David Soto, Prapti Vyas, Akinola Emmanuel, Matthew Theisen, Karolina Kosakowska, Maja Sedic, Rajat Das, Muthusamy Jayaraman, Megan Hoban, Joe Bolen and Isin Dalkilic-Liddle, Orna Therapeutics, watertown, MA
Background/Purpose: Recently, traditional ex vivo-generated chimeric antigen receptor T (CAR-T) cell therapies have shown success in the clinic for autoimmunity indications. However, manufacturing, safety, and…
Abstract Number: 0975 • ACR Convergence 2025
Linezolid prevents fibroblast activation and ameliorates tissue fibrosis by inhibition of mitochondrial translation
Xuezhi Hong¹, Yanhua Xiao², shihao zhu³, Tim Filla⁴, Andrea-Hermina Györfi⁵, Yi-Nan Li⁶, Meilin Xu⁷, Langxian Zhi², Thuong Trinh-Minh⁸, Clara Dees⁹, Georg Schett¹⁰, Jörg Distler¹¹ and Alexandru-Emil Matei¹², ¹Department of Rheumatology, University Hospital Dusseldorf, Medical Faculty of Heinrich Heine University, Dusseldorf, Germany, Düsseldorf, Germany, ²Medical Faculty of Heinrich Heine University, Dusseldorf, Germany, ³Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany, ⁴Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Germany, ⁵Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany, ⁶University Hospital of Düsseldorf, Düsseldorf, Germany, ⁷Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany, Düsseldorf, Germany, ⁸Clinic for Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Nordrhein-Westfalen, Germany, ⁹Department of Internal Medicine ³, Rheumatology and Clinical Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ¹⁰Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ¹¹University Hospital Duesseldorf and HHU, Duesseldorf, Germany, ¹²Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany, Düsseldorf, Germany
Background/Purpose: Systemic sclerosis (SSc) is a progressive fibrotic disease characterized by fibroblast activation and immune dysregulation, with limited therapeutic options. Mitochondrial dysfunction is increasingly implicated…
Abstract Number: 0940 • ACR Convergence 2025
Resident Macrophages Localize Near Fibroblasts and Drive Reprogramming in Lupus Nephritis Through Direct and Soluble Signaling
Chirag Raparia¹, Paul Hoover², Arnon Arazi³, Nir Hacohen⁴ and Anne Davidson¹, ¹Feinstein Institutes for Medical Research, Manhasset, NY, ²Brigham and Women's Hospital, Boston, MA, ³Feinstein Institutes for Medical Research, Acton, MA, ⁴Broad Institute of MIT Harvard, Cambridge, MA
Background/Purpose: Lupus nephritis (LN) is a severe manifestation of SLE that can progress to renal fibrosis, and eventual renal failure. In LN, tubulointerstitial inflammation and…
Abstract Number: 0035 • ACR Convergence 2025
Clinical and Transcriptomic Heterogeneity in Patients With RA: A Multi-Centric International Study of Anti-TNF Response
Maryna Borshchivska¹, Thibault Helleputte¹, Laurent Meric de Bellefon², Silvana di Romana³, Elsa Vieira-Sousa⁴, Vasco Romão⁴, João Eurico Fonseca⁵, Alla Ishchenko⁶, Patrick Verschueren⁶, Ruth Wittoek⁷, Peggy jacques⁷, Dirk Elewaut⁸, Bernard Lauwerys⁹ and Patrick Durez¹⁰, ¹DNAlytics, Louvain-la-Neuve, Belgium, ²Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatologie, Brussels, Belgium, ³Department of Rheumatology, Saint Pierre University Hospital, Brussels, Belgium, ⁴Faculdade Medicina, Universidade de Lisboa, ULS Santa Maria, Centro Académico Medicina de Lisboa, Lisboa, Portugal, ⁵Faculdade Medicina, Universidade de Lisboa, ULS Santa Maria, Centro Académico Medicina de Lisboa, Lisboa, Lisboa, Portugal, ⁶Rheumatology, University Hospital Leuven and Skeletal Biology and Engineering Research Centre, KU Leuven, Leuven, Belgium, ⁷VIB Center for Inflammation Research, Ghent University and Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁸VIB Center for Inflammation Research, and Ghent University Hospital, Department of Rheumatology, Ghent, Belgium, ⁹Systemic and Inflammatory Rheumatic Diseases Section, Institute of Experimental and Clinical Research (IREC), UCLouvain, Brussels, Belgium, ¹⁰Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatologie, Brussels, Brussels Hoofdstedelijk Gewest, Belgium

Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease that can lead to joint damage and disability. Although methotrexate is the standard first-line treatment, about…
Abstract Number: 0622 • ACR Convergence 2025
Shrinking Lung Syndrome in Systemic Lupus Erythematosus: A Pooled Database Analysis of Clinical, Immunological and Therapeutic Factors Impacting Outcomes
Malvika Gupta¹ and Chander Raman², ¹Mayo Clinic, Rochester MN, Rochester, MN, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Shrinking Lung Syndrome (SLS) is a rare pulmonary complication of systemic lupus erythematosus (SLE), characterized by unexplained dyspnea, pleuritic chest pain, loss of lung…
Abstract Number: 0950 • ACR Convergence 2025
Ep300-Catalyzed Rad50 Lactylation Compromises Genomic Stability and Drives CD4+T cells Cell Senescence in SLE
mingyang zhang¹, huanzi dai², cun lan³ and mingyang sun³, ¹Daping Hospital, Army Medical University, chongqing, Chongqing, China (People's Republic), ²Daping Hospital & Research Institute of Surgery, Army Medical University, Chongqing, PR China., Chongqing, China (People's Republic), ³Daping Hospital, Army Medical University, chongqing, China (People's Republic)
Background/Purpose: Senescent CD4+ T cells are increasingly implicated in systemic lupus erythematosus (SLE) pathogenesis. While metabolic reprogramming in lupus T cells enhances glycolysis and lactate…
Abstract Number: 0650 • ACR Convergence 2025
Obinutuzumab Demonstrates Steroid-Sparing Effects and Consistent Benefit In Patients with Lupus Nephritis When Using Multiple Primary Endpoint Definitions: A Secondary Analysis of Phase III Trial Results
Brad Rovin¹, Jay Garg², Richard Furie³, Rachel Jones⁴, Amit Saxena⁵, Pasquale Esposito⁶, Elsa Martins⁷, Claire Petry⁷, Nicolas Frey⁷, Bongin Yoo², Imran Hassan⁸, Thomas Schindler⁷, Theodore Omachi⁹, William Pendergraft², Mittermayer Santiago¹⁰, Gustavo Aroca Martínez¹¹ and Ana Malvar¹², ¹The Ohio State University, Columbus, OH, ²Genentech, Inc., South San Francisco, CA, ³Division of Rheumatology, Northwell Health, Great Neck, NY, ⁴Renal Medicine, Cambridge University Hospitals, Cambridge, England, United Kingdom, ⁵Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, ⁶Clinica Nefrologica, Dialisi, Trapianto, Department of Internal Medicine, University of Genoa and IRCCS Ospedale Policlinico San Martino, Genova, Italy, ⁷F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁸Hoffmann-La Roche Ltd, Mississauga, ON, Canada, ⁹Genentech, Inc., South San Francisco, ¹⁰Bahiana School of Medicine and Public Health and UFBA, Federal University of Bahia, and Clínica SER da Bahia, Salvador, Bahia, Brazil, ¹¹Universidad Simón Bolívar, Barranquilla, Colombia y Clínica de la Costa, Barranquilla, Colombia, ¹²Organización Médica de Investigación, Buenos Aires, Argentina
Background/Purpose: The Phase III REGENCY study (NCT04221477) demonstrated superiority of obinutuzumab (OBI) over placebo (PBO) in achieving complete renal response (CRR) at Week 76 when…
Abstract Number: 0526 • ACR Convergence 2025
Identification of Urine Proteomic Biomarkers Associated with Ankylosing Spondylitis
Chang-Nam Son¹, Dong-Ki Jang², So-Hye Nam³, Yoon-Jeong Oh⁴, Sungsin Jo⁵, Jong-Seo Kim⁶ and Tae-Hwan Kim⁷, ¹UIJEONGBU EULJI MEDICAL CENTER, EULJI UNIVERSITY, UIJEONGBU, Republic of Korea, ²School of Biological Sciences, Seoul National University, Seoul, Republic of Korea, ³Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keimyung University, Daegu, Republic of Korea, ⁴Uijeongbu Eulji Medical Center, Eulji University School of Medicine, Uijeongbu, Republic of Korea, ⁵Department of Biology, Soonchunhyang University, Asan,, Republic of Korea, ⁶School of Biological Sciences, Seoul National University, Seoul, ⁷Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea
Background/Purpose: Currently available diagnostic tests for inflammatory arthritis lack sufficient sensitivity and specificity, often requiring the integration of clinical manifestations with physician expertise for accurate…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].